We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01078792
First Posted: March 2, 2010
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hillel Yaffe Medical Center
  Purpose
To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.

Condition Intervention
Pulmonary Disease, Chronic Obstructive Disease Exacerbation Pulmonary Embolism Prothrombin Fragments Other: CT pulmonary angio, blood tests

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Groups/Cohorts Assigned Interventions
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
Other: CT pulmonary angio, blood tests

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients admitted to hospital due to COPD exacerbation
Criteria

Inclusion Criteria:

  • COPD exacerbation
  • Able to give informed consent
  • Able to perform spirometry

Exclusion Criteria:

  • Known malignancy
  • Known hypercoagulable state
  • Receiving anticoagulant treatment
  • Pregnancy
  • Renal failure
  • Allergy to Iodine
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078792


Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: M Beckerman, MD       marinellab@hy.health.gov.il   
Principal Investigator: M Beckerman, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Marinella Beckerman, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01078792     History of Changes
Other Study ID Numbers: 0001-10
First Submitted: March 1, 2010
First Posted: March 2, 2010
Last Update Posted: March 2, 2010
Last Verified: March 2010

Additional relevant MeSH terms:
Lung Diseases
Embolism
Pulmonary Embolism
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Disease Progression
Respiratory Tract Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive